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Objective.Despitetheuseofanticoagulationduringleftatrial(LA)ablationprocedures,ischemiccerebrovascularaccidents(CVAs)
arerecognizedasaseriouscomplication.Heparinisusuallygivenaftersafetransseptalaccesshasbeenobtained,resultinginashort
unprotected dwell time of catheters within the LA, which may account for CVAs. We investigated the frequency of CVAs and LA
thrombus formation as detected by intracardiac ultrasound (ICE) depending on the timing of heparin administration. Methods
and Results. Sixty LA ablation procedures with the use of ICE were performed in 55 patients. Patients were grouped by heparin
administrationafter(GroupI,n = 13)andbefor e(G r oupII,n = 47)transseptalaccess.GroupIpatientswereyounger(56.6±13.7
versus 65.9±9.9years,P = .01);otherclinicalandechocardiographiccharacteristicsdidnotdiﬀerbetweengroups.Earlythrombus
formation was observed in 2 (15.4%) of group I patients as compared to 0% of group II patients (P = .04). One CVA (2.1%)
occurred in one group II patient without prior thrombus detection, and none occurred in group I patients (P = ns). Conclusion.
Early administration of heparin reduces the risk of early intracardiac thrombus formation during LA ablation procedures. This
did not result in reduced rate of CVAs.
1.Introduction
After the initial description of the role of the pulmonary
veins in initiating and maintaining atrial ﬁbrillation (AF)
[1], increasing clinical evidence of eﬃcacy and safety of left
atrial ablation has been gathered [2]. Consequently, catheter
ablation of AF is performed in increasing numbers and
centers [3, 4]. Despite this increase in experience and the
rapid development of novel tools to facilitate the procedure
and improve success rates, the procedure remains complex
mainlydueto(a)theneedfortransseptalaccess,(b)thevari-
able left atrial anatomy, and (c) the possible risk of serious
periprocedural complications, including cerebral embolism.
A major concern is the development and embolism of
intracardiac thrombi during the procedure with the possible
risk of stroke. Therefore, the use of heparin with an activated
clotting time (ACT) of 300–400s is mandatory and endorsed
by current guidelines [5]. Despite this, the reported rate
of peri-interventional cerebrovascular accidents ranges from
0t o7 %[ 5]. The administration of heparin is commonly
startedaftersafetransseptalaccesshasbeenobtainedinorder
not to aggravate a possible, transseptal, puncture-related
pericardial eﬀusion. This however results in a short dwell
time of foreign material within the left atrium without eﬀec-
tive anticoagulation, which may be suﬃcient for thrombus
formation and which thus may account for the still evident
risk of embolism. Therefore, we sought to evaluate the pos-
sible beneﬁts of early versus late heparin administration
in regard to intracardiac thrombus formation as assessed
by intracardiac echocardiography (ICE). Intracardiac ech-
ocardiography can be safely used throughout invasive proce-
dures to visualize intracardiac structures, monitor transsep-
tal puncture and intracardiac catheters as well as energy
delivery, early detect complications, and possibly avoid
adverse events [6–8]. The value of ICE in monitoring
the left atrium for intracardiac thrombi has previously
been demonstrated and is therefore used in this study to
investigate the presence of thrombi depending on peri-in-
terventional anticoagulant treatment.2 Cardiology Research and Practice
2.MaterialsandMethods
2.1.Patients. Inthisobservationalstudy,weincluded60con-
secutive AF ablation procedures in 55 patients (5 Re-Do
procedures), which were performed with the use of ICE.
All patients suﬀered from symptomatic, drug-refractory AF.
Please refer to Table 1 for patient characteristics. One day
prior to the ablation procedure, transesophageal echocar-
diography (TEE) was performed in all patients to rule out
intracardiac thrombi. Emptying velocity of the left atrial
appendage was determined by pulsed wave Doppler during
TEE. All patients underwent pulmonary vein isolation
without additional lesion sets after written informed consent
was obtained.
2.2. Procedure. Oral anticoagulation was stopped prior to
the ablation procedure until the international normalized
ratio dropped below 1.5. Overlapping low molecular weight
heparin was given in body-weight adjusted doses. All pro-
cedures were performed under conscious sedation. Vascular
access was obtained via the left femoral vein for insertion
of a decapolar, 4F coronary sinus catheter (Inquiry, St. Jude
Medical, USA), and the 10F ICE catheter (AcuNav, Siemens,
Germany). The right atrium, interatrial septum, left atrium,
mitralandaorticvalves,leftatrialappendage,andtheleftand
right pulmonary veins were visualized by ICE. Subsequently,
transseptal sheaths were advanced via the right femoral vein
into the right atrium, and, after transseptal access, into the
left atrium. Transseptal sheaths were continuously ﬂushed
with heparinised saline. Catheters for mapping and ablation
wereadvancedviathetransseptalsheathsintotheleftatrium.
We used either a CARTO guided approach (n = 26)
with a circular mapping catheter (Lasso, Biosense Webster,
Diamond Bar, USA) and an open irrigated tip ablation
catheter(NaviStarThermoCool,BiosenseWebster,Diamond
Bar, USA), or a duty-cycled circular mapping and ablation
catheter (n = 34, Pulmonary Vein Ablation Catheter,
Ablation Frontiers, USA). Heparin was administered after
transseptal access as a bolus of 100U/kg in the ﬁrst 13
procedures (Group I, “late heparin”) and in all following
47 procedures (Group II, “early heparin”) as a bolus of
4000–5000U after puncture of the femoral veins but before
transseptalaccess,followedbyanotherbolusaftertransseptal
access with a cumulative target dose of 100U/kg. Heparin
was then continuously administered to achieve an ACT of
300–400s. ACT was measured 15min after transseptal access
and every 15–30min thereafter. Catheters were guided by an
electroanatomical map whenever available, by intermittent
ﬂuoroscopy and by continuous monitoring of the ICE
images.Specialattentionwaspaidtoverifycorrectandstable
catheter positions in the ICE images and to continuously
monitor for possible side eﬀects such as pericardial eﬀusion,
intracardiac thrombi, and showers of bubbles suggestive
for tissue overheating. Endpoint of the procedure was pul-
monary vein isolation as determined by loss of pulmonary
vein potentials and entrance block.
2.3. Statistics. All variables are presented ± standard devia-
tion. Data were analysed for Gaussian distribution using the
D’Agostino-Pearson normality test. Subsequent comparison
was performed using the Mann-Whitney test for variables
with non-Gaussian distribution or the unpaired t-test for
gaussian distribution, respectively. Fishers test was per-
formed for comparison of discrete variables. A P-value <.05
was considered signiﬁcant.
3. Results and Discussion
3.1. Patient Characteristics. Patient characteristics are shown
in Table 1. Patients in group I were younger (56.6 ± 13.7
versus 65.9 ± 9.9y e a r s ,P = .01). Other baseline factors such
as gender (76.9% versus 61.7% males, P = .51), type of AF
(46.2% versus 65.9% paroxysmal, P = .21), CHADS2-Score
(1.5±1.1v ersus1.5±1.1,P = .91),historyofcerebrovascular
event (30.8% versus 12.8%, P = .20), hypertension (76.9%
versus 70.2%, P = .74), diabetes (0% versus 12.8%,
P = .32), and coronary artery disease (15.4% versus 27.7%,
P = .48) did not diﬀer between groups. Echocardiographic
parameters such as left atrial diameter (46.9 ± 9.0v e r s u s
45.1 ± 7.0mm, P = .65), left ventricular ejection fraction
(51.2±9.8v e r s u s5 1 .7±8.8%, P = .74), left ventricular end-
diastolic diameter (51.4±5.6v e r s u s5 2 .7±9.4mm, P = .98),
wall thickness of septum (10.8 ± 1.2v e r s u s1 0 .7 ± 1.5mm,
P = .61), posterior wall (10.5 ± 1.9v e r s u s1 0 .8 ± 1.3mm,
P = .62), and maximal emptying velocity of the left atrial
appendage (41.2 ±11.6v e r s u s4 8 .5 ±17.1cm/s) also did not
diﬀer between groups.
3.2. Observations by Intracardiac Ultrasound. In 2/13
(15.4%) group I patients as compared to 0% of group II
patients, intracardiac thrombi were detected (P = .04).
Classiﬁcationofthrombuswasmadebecauseofindependent
mobility and tissue characteristics consistent with thrombus.
One thrombus adhered to a circular mapping catheter
(Figure 1), the other thrombus was visualized adherent
to a transseptal sheath (Figure 2). In both cases, thrombi
were detected early after transseptal access and before ra-
diofrequency energy delivery. Disruption of the endocardial
surface by radiofrequency ablation thus cannot be re-
sponsible for thrombus formation. The thrombus attached
to the transseptal sheath was detected before administration
of heparin, whereas the thrombus which was attached to
the circular mapping catheter was detected after heparin
administration. In the latter case, ACT measured immedi-
ately after thrombus detection was 289s. These two patients
did not diﬀer regarding baseline parameters from the whole
group. In both cases, additional heparin was given to achieve
an ACT > 300s. Sheaths and catheters were retracted to
the right atrium while strong suction was applied to the
sheath’s sidearm, carefully ﬂushed, and another transseptal
puncture performed. No thrombi could be detected in the
aspirate, neither were any clinical signs suggestive of central,
peripheral, or pulmonary embolism noted.
Based on the frequent observation of thrombi, we
changed the anticoagulatory regimen to administration of
heparin before transseptal access and a subsequent bolus
after transseptal access to reach a target dose of 100U/kg.
In all following procedures, no intracardiac thrombi couldCardiology Research and Practice 3
Table 1: Patient characteristics.
All Group I Group II P
“late heparin” “early heparin”
n 60 (100%) 13 (21.7%) 47 (78.3%)
Age (years) 63.9 ± 11.3 56.6 ± 13.7 65.9 ± 9.9 .01
Male gender (n) 39 (65.0%) 10 (76.9%) 29 (61.7%) .51
Paroxysmal AF (n) 37 (61.7%) 6 (46.2%) 31 (65.9%) .21
CHADS2 Score 1.5 ± 1.1 1.5 ± 1.1 1.5 ± 1.1 .92
Hx CVA (n) 10 (16.7%) 4 (30.8%) 6 (12.8%) .2
Hypertension (n) 43 (71.7%) 10 (76.9%) 33 (70.2%) .74
Diabetes (n) 6 (10%) 0 6 (12.8%) .32
CAD 15 (25%) 2 (15.4%) 13 (27.7%) .48
Echo-Parameters
LV-EF (%) 51.6 ± 8.9 51.2 ± 9.8 51.7 ± 8.8 .74
LA diameter (mm) 45.5 ± 7.5 46.9 ± 9.0 45.1 ± 7.0 .65
LVEDD (mm) 52.4 ± 8.7 51.4 ± 5.6 52.7 ± 9.4 .98
IVSd (mm) 10.7 ± 1.4 10.8 ± 1.2 10.7 ± 1.5 .61
PWd (mm) 10.7 ± 1.5 10.5 ± 1.9 10.8 ± 1.3 .62
LAA Vmax (cm/s) 47.0 ± 16.3 41.2 ± 11.6 48.5 ± 17.1 .24
Initial ACT (s) 290.1 ± 67.8 244.3 ± 40.7 301.7 ± 68.7 .002
Mean ACT (s) 315.0 ± 43.7 297.9 ± 40.9 319.4 ± 43.7 .11
AF: atrial ﬁbrillation, Hx CVA: history of cerebrovascular event, CAD: coronary artery disease, LV-EF: left ventricular ejection fraction, LA: lefta t r i u m ,
LVEDD: left ventricular end-diastolic diameter, IVSd: interventricular septum thickness, PWd: posterior wall thickness, LAA Vmax: left atrial appendage
maximal ﬂow velocity, and ACT: activated clotting time.
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Figure 1: The circular mapping catheter can clearly be visualized
in the antrum of the left superior pulmonary vein. Attached to the
inferiorpartoftheringofelectrodes,amobilethrombuscanclearly
be seen (encircled). Immediately measured ACT was 289s.
be observed. Due to the fact that the ﬁrst ACT was mea-
sured 15min after transseptal access rather than heparin
administration, it was signiﬁcantly shorter in group I than in
group II (244.3±40.7 versus 301.7±68.7s,P = .002). Mean
ACTs during the procedure did not diﬀer between groups
(297.9 ±40.9 versus 319.4 ±43.7, P = .11).
3.3. Complications. We observed one cardiac tamponade
with the need for pericardiocentesis, which occurred during
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Figure2:Amobilethrombus(encircled)isattachedtothetipofthe
transseptal sheath before the advancement of a catheter and before
heparin administration.
ablation on the ridge between the left atrial appendage and
theleftsuperiorpulmonaryvein.Thepatientrecoveredwith-
out sequelae. No tamponade occurred during transseptal
puncture.
O n ep e r i p r o c e d u r a ls t r o k eo c c u r r e di no n eg r o u pI Ip a -
tient (1/47; 2.1%) in whom we did not observe an intrac-
ardiac thrombus formation during ICE monitoring. The
patient complained about diﬃculties speaking without any
further neurologic deﬁcits. While initial examination by the
neurologist and cerebral imaging by computed tomography4 Cardiology Research and Practice
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Figure 3: Histogram showing incidence of left atrial (LA) thrombi,
cerebrovascular accidents (CVA), and the combined event rate. LA
thrombi occurred more frequently in group I patients (P = .04).
immediately after the procedure did not show signs of cere-
bral ischemia, repeat imaging on the next day revealed an
ischemic area in the cerebellum. Fortunately, the patient
fully recovered. In this patient, a thrombus in the left atrial
appendagewasseen2.5monthsbeforetheprocedure.Hewas
thenanticoagulated,andtherepeatTEEbeforetheprocedure
did not show an intracardial thrombus.
3.4. Total Event Rate. We observed intracardiac thrombi in
2 group I patients (2/13; 15.4%) versus none in group II
patients (0%; P = .04) and one CVA in one group II patient
(1/47; 2.1%) versus none in group I patient (0%, P = ns),
resultinginatotaleventrateof15.4%inGroupIversus2.1%
in group II (P = .11) (Figure 3).
4. Discussion
The use of eﬀective anticoagulation is out of question during
left atrial ablation procedures in order to minimize the risk
of thrombus formation and embolism [5]. Despite the use
of anticoagulation, the risk of periprocedural stroke reported
ranges from 0% to 7% [5, 9, 10], with most of these
occurring within 24h of the ablation procedure. Predictors
of periprocedural stroke seem to be a CHADS-Score ≥2a n d
the history of a cerebrovascular accident [10]. Subclinical
embolism as detected by magnetic resonance tomography in
clinically asymptomatic patients has been reported in 11% of
patients after left atrial ablation, with risk factors being left
ventricular hypertrophy, left ventricular dilatation, and the
presence of coronary artery disease [11].
It is common practice to start administration of heparin
after transseptal access has been obtained safely, in order
not to aggravate a possible pericardial eﬀusion related to
transseptalpuncture.ThisapproachisendorsedbyaGerman
consensus document on peri- and postinterventional stroke
during cardiac catheter procedures [12]. However, the short
dwell time of foreign material within the slow ﬂow area of
the left atrium may be suﬃcient for thrombus formation.
Of note, measurements of ACTs in our study show that
whenever the operator decides to administer heparin after
transseptal access, the patient is exposed to an increased risk
of left atrial thrombus due to suboptimal ACT levels (244
versus 301, P = .002) for at least 15 minutes. The presented
data show an incidence of 15.4% of thrombi adherent to
sheaths and catheters within the left atrium almost imme-
diately after left atrial access when heparin was given after
transseptal puncture, as compared to an incidence of 0%
when heparin was given before transseptal access. The most
likely mechanism for thrombus formation is the presence of
foreign material within the left atrium, since both thrombi
(a) were adherent to sheaths and catheters, respectively, and
(b)weredetectedearlybeforeenergydeliveryatapointwhen
no endothelial disruption induced by ablation had occurred.
Clinical characteristics previously described as risk factors
for periprocedural stroke or subclinical embolism did not
diﬀer between these groups. Ren et al. found an incidence of
left atrial thrombi as detected by ICE in 10.3% of patients,
in all of whom heparin was given after transseptal access
[13]. Our observed incidence is also comparable to another
study, which found left atrial thrombi in 9.1% of cases, when
heparin was given after the second transseptal puncture, as
compared to 0% when heparin was given before transseptal
access[14].Inthisretrospectiveanalysis,possibleclinicalrisk
factors of embolism as described above and the intensity of
anticoagulation were not evaluated. However, our data and
the data provided by Ren et al. [13] and Bruce et al. [14]
strongly suggest that (a) ICE is useful in thrombus detection
and (b) thrombus formation must be expected in 10–15% of
cases when heparin is given after transseptal access.
In these studies, as well as in our population, removal
of sheaths to the right atrium while applying suction and
careful ﬂushing was safe and did not provoke clinical evi-
dent embolism. Similarly to other authors, we believe that
immediate withdrawal of the thrombus by retraction of
sheaths and catheters, respectively, is the best strategy once
a thrombus has been detected, since further manipulation
of catheters carries the risk of thrombus dislodgement and
embolism.
The only clinical evident embolism in our series of pa-
tients developed in a group II patient in whom no intracar-
diac thrombus was detected prior to embolism. The overall
combined event rate of thrombus detection and clinical
evident embolism therefore was not signiﬁcantly diﬀerent;
however, this retrospective study might be underpowered
to detect such a diﬀerence. Still, it might be that heparin
administration, even if started early, might not be the opti-
mal strategy for periprocedural anticoagulation. It remains
unclearwhethertheobservationofanintracardiacthrombus
is predictive of embolism, however, it seems to be intuitive
to avoid such a thrombus formation. An association of left
atrial thrombus and embolism was also not be found in
other studies [13, 14], which may be related to (a) theCardiology Research and Practice 5
small number of LA thrombi overall detected, (b) the early
detection by ICE and subsequent removal, or (c) subclinical
embolism. Of note, subclinical embolism has been described
with an equivalent incidence as LA thrombi [11].
Continued oral anticoagulation with a therapeutic INR
at the time of ablation is another strategy for peri-inter-
ventional management of anticoagulation. Low event rates
of embolism as well as bleeding have been described in
experienced centers, and this evidence supports the strategy
of maintaining therapeutic levels of oral anticoagulation
during ablation procedures [15–17]. Current evidence also
shows that cardiac tamponade is not more frequent, more
severe, or more diﬃcult to manage when occurring during
continued oral anticoagulation [17, 18].
5. Conclusions
Intracardiacthrombusformationisfrequentwhenheparinis
administered after transseptal access and not associated with
previously described risk factors for clinical and subclinical
embolism.Earlyadministrationofheparin(i.e.,beforetrans-
septalaccess)diminishesthisriskbutdidnotaﬀecttherateof
CVAs in this study. Further prospective investigation should
address the issue whether early peri-interventional anticoag-
ulation reduces the risk of embolism and stroke.
5.1.Limitations. Thestudyresultsmustbeappraisedaccord-
ingtotheretrospectiveandnonrandomizedstudydesignand
the low event rate. Additionally, despite consequent obser-
vation of the ICE images, as a two-dimensional imaging
modality, ICE cannot continuously monitor the whole body
of the left atrium. Therefore, we cannot exclude that thrombi
developedinanunmonitoredpartoftheleftatriumandthus
would have been overlooked.
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